TransMedics Group (TMDX) Competitors $123.73 -4.77 (-3.71%) As of 10:32 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TMDX vs. SNN, SOLV, PEN, STVN, GKOS, BLCO, SLNO, IRTC, INSP, and NVSTShould you be buying TransMedics Group stock or one of its competitors? The main competitors of TransMedics Group include Smith & Nephew SNATS (SNN), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), Bausch + Lomb (BLCO), Soleno Therapeutics (SLNO), iRhythm Technologies (IRTC), Inspire Medical Systems (INSP), and Envista (NVST). These companies are all part of the "medical equipment" industry. TransMedics Group vs. Its Competitors Smith & Nephew SNATS Solventum Penumbra Stevanato Group Glaukos Bausch + Lomb Soleno Therapeutics iRhythm Technologies Inspire Medical Systems Envista TransMedics Group (NASDAQ:TMDX) and Smith & Nephew SNATS (NYSE:SNN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability. Do institutionals & insiders hold more shares of TMDX or SNN? 99.7% of TransMedics Group shares are held by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are held by institutional investors. 7.0% of TransMedics Group shares are held by insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more risk & volatility, TMDX or SNN? TransMedics Group has a beta of 2.09, meaning that its stock price is 109% more volatile than the S&P 500. Comparatively, Smith & Nephew SNATS has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Does the media refer more to TMDX or SNN? In the previous week, TransMedics Group had 27 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 30 mentions for TransMedics Group and 3 mentions for Smith & Nephew SNATS. Smith & Nephew SNATS's average media sentiment score of 1.08 beat TransMedics Group's score of 0.68 indicating that Smith & Nephew SNATS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 9 Very Positive mention(s) 4 Positive mention(s) 14 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Smith & Nephew SNATS 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate TMDX or SNN? TransMedics Group currently has a consensus target price of $123.00, indicating a potential downside of 0.59%. Smith & Nephew SNATS has a consensus target price of $28.00, indicating a potential downside of 19.85%. Given TransMedics Group's stronger consensus rating and higher possible upside, research analysts plainly believe TransMedics Group is more favorable than Smith & Nephew SNATS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransMedics Group 0 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.78Smith & Nephew SNATS 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is TMDX or SNN more profitable? TransMedics Group has a net margin of 13.49% compared to Smith & Nephew SNATS's net margin of 0.00%. TransMedics Group's return on equity of 28.02% beat Smith & Nephew SNATS's return on equity.Company Net Margins Return on Equity Return on Assets TransMedics Group13.49% 28.02% 8.64% Smith & Nephew SNATS N/A N/A N/A Which has stronger earnings & valuation, TMDX or SNN? Smith & Nephew SNATS has higher revenue and earnings than TransMedics Group. Smith & Nephew SNATS is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTransMedics Group$441.54M9.55$35.46M$1.9364.11Smith & Nephew SNATS$5.81B2.63$412M$2.1616.17 SummaryTransMedics Group beats Smith & Nephew SNATS on 13 of the 17 factors compared between the two stocks. Get TransMedics Group News Delivered to You Automatically Sign up to receive the latest news and ratings for TMDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TMDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TMDX vs. The Competition Export to ExcelMetricTransMedics GroupMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.23B$6.81B$5.55B$9.55BDividend YieldN/A1.31%4.73%4.14%P/E Ratio64.2621.7229.0924.51Price / Sales9.5555.09374.9979.89Price / Cash73.2620.8324.4827.20Price / Book18.174.718.675.84Net Income$35.46M$176.39M$3.24B$264.99M7 Day Performance18.03%-1.82%0.13%-0.57%1 Month Performance-3.88%-3.10%7.85%6.32%1 Year Performance-16.65%14.83%29.74%24.00% TransMedics Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TMDXTransMedics Group2.4701 of 5 stars$123.73-3.7%$123.00-0.6%-14.4%$4.23B$441.54M64.26210News CoverageEarnings ReportAnalyst UpgradeSNNSmith & Nephew SNATS3.0555 of 5 stars$31.30-1.2%$28.00-10.5%+1.1%$13.71B$5.81B14.4917,349News CoveragePositive NewsSOLVSolventum1.3757 of 5 stars$74.15-0.8%$84.38+13.8%+27.8%$12.82B$8.25B34.3022,000Positive NewsUpcoming EarningsPENPenumbra4.6703 of 5 stars$233.73+0.3%$305.07+30.5%+37.1%$9.04B$1.19B220.134,500Earnings ReportAnalyst DowngradeSTVNStevanato Group2.1729 of 5 stars€26.25-1.0%N/A+33.2%€7.95B€1.19B51.475,521News CoverageGKOSGlaukos4.0151 of 5 stars$94.52+0.2%$134.67+42.5%-24.6%$5.41B$383.48M-39.92780Earnings ReportBLCOBausch + Lomb2.9216 of 5 stars$14.55+1.6%$15.45+6.2%-15.7%$5.15B$4.79B-14.1313,500Earnings ReportSLNOSoleno Therapeutics4.2209 of 5 stars$86.53+0.1%$108.70+25.6%+72.6%$4.36BN/A-18.7430Positive NewsUpcoming EarningsIRTCiRhythm Technologies1.8119 of 5 stars$134.40+0.2%$137.30+2.2%+123.3%$4.29B$618.59M-42.802,000Earnings ReportINSPInspire Medical Systems4.4602 of 5 stars$129.38+0.4%$208.55+61.2%-12.6%$3.82B$802.80M59.631,246Trending NewsEarnings ReportAnalyst ForecastGap DownNVSTEnvista3.5931 of 5 stars$20.91+0.5%$20.23-3.2%+22.9%$3.54B$2.51B-3.2012,300Trending NewsEarnings ReportAnalyst UpgradeAnalyst Revision Related Companies and Tools Related Companies Smith & Nephew SNATS Alternatives Solventum Alternatives Penumbra Alternatives Stevanato Group Alternatives Glaukos Alternatives Bausch + Lomb Alternatives Soleno Therapeutics Alternatives iRhythm Technologies Alternatives Inspire Medical Systems Alternatives Envista Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TMDX) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWall Street Hates This Gold IRA Strategy—Here’s WhyWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransMedics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransMedics Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
